

Dear Colleague,

## Haemato-Oncology Genomic Testing from 1<sup>st</sup> April

On 1<sup>st</sup> April 2021 the National Test Directory for cancer will go live, which includes the genomic tests commissioned by the NHS in England for patients with suspected or confirmed haematological malignancies.

The National Genomic Test Directory for cancer is available here: <https://www.england.nhs.uk/publication/national-genomic-test-directories/>

Testing will continue to be delivered for the North West Genomic Laboratory Hub (NW-GLH) as part of the existing specialist, integrated Haematological Malignancy Diagnostic services: Haematological Cancer Diagnostic Partnership (HCDP) service at Manchester Foundation Trust & Christie Foundation Trust and Haemato-Oncology Diagnostic Service (HODS) at Liverpool Clinical Laboratories & Liverpool Women's Hospital.

The NW-GLH receives central funding from NSHE for providing the commissioned genomic tests removing provider-to-provider charging.

Test requests should be submitted as before via the dedicated HODS systems following the testing pathways and guidance provided therein. Reports will be returned via the HODS integrated reporting system or by nhs.net email if access to HODS has not yet been set up.

To request access in Greater Manchester please return the HODS user form to [Labs.SD@mft.nhs.uk](mailto:Labs.SD@mft.nhs.uk), GM users can also contact MFT Labs IT Service Desk – 0161 276 4079. To request access in Cheshire and Merseyside please contact [HODSenquiries@rlbuht.nhs.uk](mailto:HODSenquiries@rlbuht.nhs.uk), for urgent enquires users can also call 0151 706 4334. Please note access can only be granted for users whose organisation is already specified on the relevant system.

The HODS testing pathways as well as the Test Directory provide guidance on clinical indication for testing and patient eligibility. The laboratory will contact you should a request fall outside the NHSE-commissioned test directory.

Please note that for a few specialist tests, samples will be referred to one of the other GLH laboratories but sample referral and reporting will be handled by the NW-GLH via the HMDS service with the exception of ALL MRD samples (adult and paediatric) which should continue to be sent according to current pathways until further notice. As the test directory will be regularly updated there may be some new or rare targets not currently available. If this is the case the laboratory will contact you to discuss testing options.

For more information please refer to our website <https://hcdp-wiki.mft.nhs.uk> or contact:

NW-GLH clinical lead Richard Chasty ([Richard.chasty@nhs.net](mailto:Richard.chasty@nhs.net)) /NW-GLH scientific lead Dörte Wren ([dorte.wren@mft.nhs.uk](mailto:dorte.wren@mft.nhs.uk))

A new NW-GLH website is under development and will be released this month: <https://mft.nhs.uk/nwglh/>

Yours sincerely,

Dörte Wren, FRCPath  
Consultant Clinical Scientist  
Lead Scientist for Haemato-Oncology, North-West Genomics Laboratory Hub

[www.mft.nhs.uk](http://www.mft.nhs.uk)

**Incorporating:**

Altrincham Hospital • Manchester Royal Eye Hospital • Manchester Royal Infirmary • Royal Manchester Children's Hospital • Saint Mary's Hospital • Trafford General Hospital • University Dental Hospital of Manchester • Wythenshawe Hospital • Withington Community Hospital • Community Services